Emcure Pharmaceuticals Ltd.
ISIN: INE168P01015 • Market Cap: ₹35,939 Cr
The 5-Pillar Quality Audit for Emcure Pharmaceuticals Ltd.
Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:
1. Profitability & Capital Efficiency
Weight: 25%Measures operating margins (20.1%), Return on Capital Employed (21.2%), and equity compounding (15.3%).
2. Financial Health & Solvency
Weight: 25%Debt-to-Equity is 0.16 with comfortable interest coverage and clean working capital.
3. Growth & Compounding Track Record
Weight: 20%Historical 3Y Sales CAGR (17.4%) and 3Y PAT CAGR (24.2%).
4. Valuation Multiple & Margin of Safety
Weight: 15%Trades at P/E of 35.53 vs PEG of 2.00 and Dividend Yield of 0.2%.
5. Ownership Quality & Governance
Weight: 15%Promoter holding stands at 77.8%, backed by 13.3% institutional ownership.
Key Fundamental Strengths
Superior Capital Efficiency (ROCE: 21.2%)
Emcure Pharmaceuticals Ltd. generates exceptional return on capital employed of 21.2%, reflecting pricing power and competitive moat.
Strong Topline Expansion (3Y Sales CAGR: 17.4%)
Revenue has expanded at 17.4% CAGR over 3 years, signaling industry market-share gains.
High-Velocity Profit Compounding (3Y PAT CAGR: 24.2%)
Net earnings have compounded at 24.2% annualized, demonstrating operating leverage.
Areas to Watch & Potential Risks
Sectoral & Macro Headwinds (Healthcare)
Subject to broader cyclical demand, raw material price shifts, and regulatory frameworks governing the Healthcare space.
Quantitative Strategy Eligibility
Checking EMCURE against established Indian wealth creation frameworks:
Coffee Can Investing Framework
Passes Saurabh Mukherjea's Coffee Can rule: 10%+ sustained revenue growth and 15%+ ROCE/ROE.
Quality Factor Screener (High RoIC + Low Debt)
Qualifies for Indian Quality Indices with overall score of 78/100 and clean gearing.
GARP / Value-Growth Blend
Valuation multiple or return metrics require further cyclical pullback.
Healthcare Sector Peer Comparison
Compare EMCURE directly against top industry peers by market capitalization:
| Company | 5-Pillar Score | Market Cap | P/E | ROCE | D/E | Scorecard |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd. (EMCURE)Current | 78/100 | ₹35,939 Cr | 35.53 | 21.2% | 0.16 | — |
| Sun Pharmaceutical Industries Ltd. (SUNPHARMA) | 77/100 | ₹4.55 Lakh Cr | 37.65 | 20.4% | 0.05 | View |
| Divi's Laboratories Ltd. (DIVISLAB) | 73/100 | ₹2.26 Lakh Cr | 77.37 | 19.4% | 0.00 | View |
| Torrent Pharmaceuticals Ltd. (TORNTPHARM) | 64/100 | ₹1.91 Lakh Cr | 87.43 | 9.5% | 1.76 | View |
| Apollo Hospitals Enterprise Ltd. (APOLLOHOSP) | 70/100 | ₹1.27 Lakh Cr | 60.55 | 19.1% | 0.62 | View |
| Cipla Ltd. (CIPLA) | 63/100 | ₹1.14 Lakh Cr | 33.94 | 16.1% | 0.01 | View |
Frequently Asked Questions: Emcure Pharmaceuticals Ltd.
Q:What is the 5-Pillar Fundamental Score for Emcure Pharmaceuticals Ltd. (EMCURE)?
Emcure Pharmaceuticals Ltd. has a RupeeTools Fundamental Score of 78/100, placing it in the 'Solid & Healthy' category. Its pillar scores are: Profitability (82/100), Financial Health (79/100), Growth (86/100), Valuation (62/100), and Ownership Quality (72/100).
Q:Is EMCURE fundamentally strong for long-term investment?
Yes, EMCURE exhibits solid fundamental strength with a 78/100 score, driven by a return on equity of 15.3% and a debt-to-equity ratio of 0.16.
Q:Does EMCURE pass the Coffee Can Investing filter?
Yes! EMCURE satisfies both core pillars of Coffee Can Investing: achieving consistently high capital returns (ROCE/ROE >= 15%) alongside double-digit multi-year revenue growth.
Q:How does EMCURE compare against other Healthcare peers?
Within India's Healthcare sector, EMCURE trades at a P/E of 35.53 and generates an ROCE of 21.2%. Compare its 5-Pillar score of 78/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Divi's Laboratories Ltd. (73/100).
Regulatory & SEBI Research Analyst Compliance Disclaimer:
This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.